Tauklarify is a new brain PET tracer that finds tau tangles, twisted tau protein deposits linked to Alzheimer's disease. In 2026 it became an FDA-approved option for cognitively impaired adults evaluated for Alzheimer's, and primary care now helps decide who should be referred for it. The approval covers florquinitau F 18 injection, formerly called MK-6240, for PET imaging of tau neurofibrillary tangle pathology.
Pharmacy Times reported that the FDA approved it on Aug. 14, 2026 for this use Pharmacy Times approval report. It does not replace a clinical exam, memory testing, or other causes of impairment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does the scan work?
- How is it different from earlier tau imaging?
- What should you ask your primary-care doctor?
- What are the limits and safety steps?
How does the scan work?
A small amount of tracer is injected into a vein before the PET scan. The tracer sticks to tau tangles and gives off a signal the scanner can map. Doctors then read the pattern as positive or negative for tau pathology. Approval rested on two studies with 617 people and five blinded readers. Pharmacy Times reported positive agreement of 68%-88%, negative agreement of 93%-99%, and strong agreement among readers Pharmacy Times approval report.
High negative agreement means a negative read was usually consistent. The tracer had a long research history before approval. NeurologyLive reported Fast Track review, FDA application acceptance in Oct. 2025, and prior research use in nearly 100 trials NeurologyLive approval report. That history helped clinics learn how to acquire and read the scans.
How is it different from earlier tau imaging?
Tauvid, or flortaucipir, was the earlier FDA-approved tau PET tracer. Tauklarify uses a different tracer molecule designed to bind tau tangles clearly. Both require a PET center and trained readers. A head-to-head study scanned the same people with both tracers.
Being Patient reported that MK-6240 found tangles earlier and separated Alzheimer's-related impairment better, with accuracy of 0.93 versus 0.86 Being Patient study summary. Earlier detection matters because tau spreads as memory and thinking worsen. Better detection does not mean perfect detection. Performance was mainly established by comparing unimpaired amyloid-negative people with impaired amyloid-positive people. Results in mixed memory-clinic cases may be less clear-cut.
What should you ask your primary-care doctor?
Primary care remains the first stop for memory concerns. The visit usually covers symptoms, medicines, sleep, mood, safety, and brief thinking tests. Imaging comes only when it would change care.
That selective approach matches current guidance for family doctors. The Alzheimer's Association issued a 19-recommendation primary-care evaluation framework in Dec. 2024, with follow-up appropriate-use criteria directing PET only when results change care or treatment eligibility. Most patients will still receive careful follow-up without a tau scan.
- Ask what else could explain the symptoms
- Ask whether amyloid testing comes first
- Ask whether a PET result would change referral or treatment eligibility
- Ask where the nearest qualified PET center is
What are the limits and safety steps?
A tau PET result is one piece of evidence. A negative scan does not rule out tau pathology, and a positive scan alone does not confirm it. The final diagnosis still joins symptoms, exam findings, and often amyloid results. Safety data are reassuring for a one-time tracer dose.
The most common events were headache in 0.7% and nausea in 0.2% among 1,734 subjects. Labeling also calls for radiation precautions, avoiding smoking and certain CYP1A2 inducers for seven days, and pausing breastfeeding for four hours. Bring a full medicine and supplement list to the imaging appointment. Tell staff about smoking, liver medicines, pregnancy, or breastfeeding before scheduling.
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Changed and What Comes Next for Primary Care Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for Primary Care Patients
- Strengths-Based Dementia Care in the 2026 NIA Report: What Changed and What Comes Next for Spouses and Partners
